Parexel expands late-phase service focus through Access division

By Dan Stanton contact

- Last updated on GMT

Market access and post-approval services combined through Parexel Access division
Market access and post-approval services combined through Parexel Access division

Related tags: Pharmaceutical industry

Parexel has reorganised its Phase IIIb/IV offerings to cope with growing demand in market access and product lifecycle services from pharma firms.

“No longer is demonstrating safety and efficacy enough to launch a product successfully,”​ Corporate Vice President and Worldwide Head of Parexel Joshua Schultz said, as pharma firms are under greater pressure to control healthcare spending.

As such, the contract research organization (CRO) has announced it is restructuring and expanding its evidence-based services with a focus on medical affairs, commercialisation and lifecycle management for pharma products, forming Parexel Access.

“The various services that make up Parexel Access have been outsourced by pharmaceutical companies for many years,”​ Schultz told Outsourcing-Pharma.com. However, substantial shifts in the market access landscape and rapid growth in demand for new sorts of data are outstripping traditional approaches and internal capabilities.”

Parexel is not alone in expanding its late-stage offerings. Rival CRO Quintiles​, for example, has positioned itself to service growing demand for such trials and last month​ penned a deal with IMS Health to access real-world data.

Furthermore, industry expert Neal McCarthy from Fairmount Partners recently told this publication​ the breadth and complexity of medical affairs and post-market studies typically led to pharma firms keeping such services in-house, but this is now changing.

Heron Acquisition

The new division combines Parexel’s medical communications and post-approval services with the commercialisation and pharmacovigilance offering acquired when the firm bought Heron Group in 2013​, which Schultz said has pushed Parexel into a greater leadership position in the market access space.

The new division will work with biopharmaceutical companies of all sizes, Schultz added, “although mid and large sized companies typically commercialise a greater percentage of the industry’s products.”

No specific investment was divulged, but Schultz said the Parexel Access “currently has several thousand individuals working within the unit and will continue to grow rapidly based upon market demand and targeted investments in key capabilities.”

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Related suppliers

Follow us

Products

View more

Webinars